2022-06-06 | NDAQ:AVGR | Press release

REDWOOD CITY, Calif. /ACCESSWIRE/June 6, 2022/ Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company commercializing the first and only catheter-based, image-guided intravascular system for the diagnosis and treatment of peripheral arterial disease (PAD) , today announced two podium presentations featuring the company’s Lumivascular technology at the annual New Cardiovascular Horizons (NCVH) conference, which ran May 31-June 3 in New Orleans.

Key opinion leaders in the fields of interventional cardiology and endovascular interventions have highlighted Avinger’s Lumivascular technology in the following sessions:

  • Dr. Ian Cawich, interventional cardiologist and director of the Vascular and Vein Institute at Arkansas Heart Hospital in Little Rock, presented Avinger’s entire portfolio of proprietary OCT-guided technologies, including the new console of Lightbox Imaging 3, in his session, “OCT-Advice for Crossing CTO and Atherectomy.”
  • Dr. Jon George, interventional cardiologist and specialist in endovascular medicine at Pennsylvania Hospital, University of Pennsylvania Health System in Philadelphia, discussed Avinger’s Pantheris SV (Small Vessel) Guided Atherectomy System in his presentation, “Utility of the Pantheris Atherectomy Device in Treating BTK Lesions.”

Dr Cawich commented: “On-board image guidance offers the endovascular specialist distinct advantages when overcoming complete blockages and treating vascular disease, resulting in safer and longer lasting outcomes for patients and less radiation for physicians and support staff. Clinical data published in peer-reviewed publications confirm the clinical benefits of OCT-guided treatment in a wide variety of lesions both above and below the knee Recent data from the INSIGHT trial are particularly striking , which showed that patients with in-stent restenosis treated with Pantheris had 89% freedom from target lesion revascularization after 12 months, significantly better than published study results for non-imaging devices.

Dr. George noted, “Arterial disease below the knee represents a significant clinical challenge due to the severity of potential complications during treatment and the high recurrence rates associated with many interventional tools. Pantheris SV, with its integrated image guidance system and small vessel lesion volume reduction approaches, represents an impactful new option for physicians to improve the durability and safety of below-the-knee procedures Interim Results of IMAGE-BTK, a post-marketing study designed to assess the safety and efficacy of Pantheris SV in the treatment of lesions below the knee, shows 93% no revascularization of the target lesion and 94% patency after 12 months with 100% absence of major adverse events. These initial results, if sustained throughout the duration of the trial, would support Pantheris SV as the new standard of care in this broad area of ​​clinical need. »

Jeff Soinsski, President and CEO of Avinger, commented, “The data and case studies that Dr. Cawich and Dr. George presented at the NCVH conference demonstrate the exceptional clinical outcomes that pioneering physicians offer their patients through our exclusive image-guided technology. We are inspired by their passion for providing the best possible care to their patients and appreciate their partnership as we continue to grow our Lumivascular portfolio.

The NCVH conference, founded in 1999, provides education in all areas related to peripheral vascular interventions, with a particular focus on critical limb ischemia and amputation prevention. The conference welcomes more than 1,500 attendees each year and includes more than 24 live case transmissions, more than 300 scientific lectures and more than 175 professors.

Avinger’s Lumivascular technology incorporates an on-board image guidance system to allow physicians, for the very first time, to see inside the artery during an atherectomy or CTO crossover procedure using an imaging modality called optical coherence tomography, or OCT. During the procedure, high-resolution intravascular OCT images are displayed on Avinger’s Lightbox console in real time to guide therapy. Physicians performing therapeutic procedures with other devices must rely solely on X-ray images and tactile feedback to guide their interventions when treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions for safe and effective outcomes, without exposing healthcare workers and patients to the negative effects of ionizing radiation.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first and only catheter-based, image-guided system for the diagnosis and treatment of patients with peripheral arterial disease (PAD). PAD is estimated to affect more than 12 million people in the United States and more than 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox series of imaging consoles, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) catheters and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Follow Avinger on Twitter and Facebook.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding patients and the benefits of our products to physicians and the adoption of our products by physicians. These statements are based on current assumptions that involve risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependence on a limited number of products; resource requirements related to our products; the timing and outcome of clinical trial results; as well as other risks described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 22, 2022 and our Quarterly Report on Form 10-Q filed in May 10, 2022. These forward-looking statements speak only as of the date hereof and should not be relied upon unduly. Avinger disclaims any obligation to update these forward-looking statements.

Investor contacts:

Matt Kreps

Darrow Associates Investor Relations

(214) 597-8200

[email protected]

Public relations contact:

Phil Preuss

Marketing Director

Avinger, Inc.

(650) 241-7942

[email protected]

THE SOURCE: Avinger, Inc.

See the source version on accesswire.com:


Comments are closed.